spacer
home > ebr > autumn 2017 > unleashing 3d
PUBLICATIONS
European Biopharmaceutical Review

Unleashing 3D

The last 10 years have seen a dramatic surge in the number of publications about organoids – but what are they and why is everyone talking about them? In simple terms, they are miniature organs grown in vitro in a near-physiological 3D environment. Unlike simple tissue cultures, they retain features of the organ they are derived from, including important structural and functional properties, and many believe that they could dramatically accelerate the understanding of human biology and disease progression.

Traditional 2D cell culture has brought great progress in understanding human development over the last 50 years. However, studying organogenesis in vitro has been hindered by the lack of appropriate systems that would allow the cell-to-cell interactions needed for organ formation. Organoids provide the accurate and physiologically relevant models that are needed to overcome this deficiency.

So-called organoids have now been derived from gut, kidney, pancreas, liver and brain tissue, and growing these mini-organs has been made possible by the recent advances in stem cell systems and the development of 3D support matrices. Thanks to this new technology, cells derived from stem cells or organ progenitors can self-organise through cell sorting and recapitulate the complexity of mammalian organogenesis in vitro in a way that is similar to how they do in vivo.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Colin Sanctuary is a biomedical engineer and Chief Executive Officer at QGel. Following his PhD in biomedical engineering at École Polytechnique Fédérale de Lausanne, Switzerland, Colin worked in product development and later in global marketing in the medical device and pharma industries. In 2009, he co-founded QGel with the aim of building a company that contributes to improving R&D productivity in pharma, particularly in the area of developing novel anticancer treatments.
spacer
Dr Colin Sanctuary
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Expands Services for Early Discovery Screening

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its service capabilities in early discovery screening. Charles River is the first contract research organization to offer clients access to Apricot Designs' Dual Arm (ADDA) system for high-throughput absorption, distribution, metabolism, and excretion (HT-ADME) to identify potential lead compounds in North America and Europe. Additionally, the Company has geographically expanded its pharmacokinetic (PK) capabilities at sites central to major pharmaceutical and biotechnology hubs.
More info >>

White Papers

Advances in Aseptic Blow-Fill-Seal Processing of Pharmaceutical Liquids Improve Product Integrity and Patient Safety

Weiler Engineering, Inc

The latest improvements in aseptic blow-fill-seal technology are providing more streamlined automation of critical B/F/S processing areas, while limiting human intervention and effectively reducing airborne microbial bioburden and particulate levels, and enhancing sterility assurance and patient safety.
More info >>

 
Industry Events

On Helix 2018

10-11 July 2018, The Cambridge Building, Babraham Research Campus

ON Helix is a two-day event aimed at informing delegates of how to turn early stage inventions and ideas into innovative health treatments (new medicines, novel biomarkers, useful medical devices or improved medical practices).
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement